141 related articles for article (PubMed ID: 8350953)
1. Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication.
Krcméry V; Danisovicová A; Drgona L; Spánik S; Fuchsberger P; Korec S; Svec J
Neoplasma; 1993; 40(2):103-5. PubMed ID: 8350953
[TBL] [Abstract][Full Text] [Related]
2. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
3. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Colardyn F
J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
Yataganas X; Rombos Y; Vayopoulos G; Meletis J; Avlami A
Chemotherapy; 1991; 37(5):376-81. PubMed ID: 1804599
[TBL] [Abstract][Full Text] [Related]
6. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.
Girmenia C; Alimena G; Latagliata R; Morano SG; Celesti F; Coppola L; Spadea A; Tosti S; Mecarocci S; D'Elia GM; Tafuri A; Cimino G; Mandelli F
Haematologica; 1999 Sep; 84(9):814-9. PubMed ID: 10477455
[TBL] [Abstract][Full Text] [Related]
7. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
8. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
Schmid L; Jeschko M; Wilder-Smith C; Schafroth U; Thürlimann B; Pedrazzini A; Senn H
Chemotherapy; 1991; 37(5):346-52. PubMed ID: 1804595
[TBL] [Abstract][Full Text] [Related]
9. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
[TBL] [Abstract][Full Text] [Related]
10. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.
Suwangool P; Aswapokee N; Sathapatayavongs B; Leelasuphasri S; Siritanaratkul N; Chuncharunee S; Chayakul P
J Med Assoc Thai; 1993 Jun; 76(6):314-8. PubMed ID: 8083623
[TBL] [Abstract][Full Text] [Related]
11. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
Charnas R; Lüthi AR; Ruch W
Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
[TBL] [Abstract][Full Text] [Related]
12. Ceftriaxone plus amikacin in neutropenic patients: a report on 100 cases.
Blanc C; Pollet JP; Bauters F
Chemotherapy; 1991; 37(5):382-8. PubMed ID: 1804600
[TBL] [Abstract][Full Text] [Related]
13. Amikacin plus ceftazidime versus amikacin plus piperacillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia.
Casali A; Ameglio F; Gionfra T; Tonachella R; Paoletti G; Gallo Curcio C
Chemioterapia; 1987 Dec; 6(6):440-4. PubMed ID: 3325175
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin plus amikacin versus cefotaxime plus amikacin in neutropenic and feverish patients with malignant hemopathies.
Pavone V; Specchia G; Guarini A; Coniglio M; Iaculli L; Girardi F; Colucci A; Liso V
Chemioterapia; 1988 Oct; 7(5):330-5. PubMed ID: 3224402
[TBL] [Abstract][Full Text] [Related]
15. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime versus a combination of amikacin and ticarcillin in the treatment of severe infections.
Limson BM; Navarro-Almario E; Litam P; Que E; Kua LT
Clin Ther; 1988; 10(5):589-93. PubMed ID: 2856601
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer.
Viscoli C; Moroni C; Boni L; Bruzzi P; Comelli A; Dini G; Fabbri A; Secondo V; Terragna A
Rev Infect Dis; 1991; 13(3):397-404. PubMed ID: 1866542
[TBL] [Abstract][Full Text] [Related]
18. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
Leoni F; Ciolli S; Pascarella A; Fanci R; Caporale R; Rossi Ferrini P
Chemotherapy; 1993; 39(2):147-52. PubMed ID: 8458248
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
